Avience Biomedicals SME IPO Details, Financials, Valuation & Peers
Explore Avience Biomedicals SME IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Avience Biomedicals Limited, incorporated in June 2024, is an ISO certified company specializing in the manufacturing, supply, and export of molecular diagnostic solutions. The company's core business revolves around biotechnology, genomics, and the In Vitro Diagnostics (IVD) industry.
Avience Biomedicals offers a comprehensive range of products and services, including IVD rapid test kits, serology products, biochemistry analyzers and reagents, molecular diagnostics (such as COVID-19 detection kits), hematology analyzers, and medical devices including oxygen concentrators and viral transport solutions. In addition to manufacturing, the company also acts as a distributor and trader of medical equipment.
Key highlights of Avience Biomedicals include:
- Diverse Product Portfolio: Offers a wide array of diagnostic solutions, from rapid test kits to advanced analyzers and molecular diagnostics.
- B2B and B2G Focus: Exclusively caters to the Business-to-Business (B2B) and Business-to-Government (B2G) markets.
- Broad Customer Base: Products serve Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas.
- Quality Assurance: Complies with ISO standards and regulatory approvals, with stringent quality control processes.
- Growing Reach: Possesses a strong distribution network across India and is expanding its international footprint.
Objects of the Issue
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
- Funding the working capital requirements of the Company
- General Corporate Purposes
- Total
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 18 Jun - 22 Jun 2026 |
| IPO Price Band | ₹196 - ₹208 per share |
| Fresh Issue | ₹28.53 crore |
| Offer For Sale | NIL |
| Total IPO Size | ₹30.24 crore |
| Face Value | ₹10 |
| Listing On | NSE SME |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 18 Jun 2026 |
| IPO Closing Date | 22 Jun 2026 |
| Basis Of Allotment | 23 Jun 2026 |
| Refunds | 24 Jun 2026 |
| Demat Transfer | 24 Jun 2026 |
| IPO Listing Date |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2024 | 31 Mar 2025 | 31 Jan 2026 |
|---|---|---|---|
| Assets | 34.65 | 56.52 | 66.07 |
| Total Income | 24.37 | 45.97 | 41.94 |
| Profit After Tax | 2.14 | 7.23 | 5.74 |
| EBITDA | 4.08 | 11.41 | 10.34 |
| NET Worth | 6.21 | 22.78 | 28.52 |
| Reserves and Surplus | 2.93 | 18.75 | 24.49 |
| Total Borrowing | 15.13 | 22.16 | 26.73 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | 6,83,400 |
| Non-Institutional Investor (NII/HNI) | 2,07,000 |
| Retail Individual Investor (RII) | 4,81,200 |
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 0.01 |
| Non-Institutional Investor (NII/HNI) | 56.19 |
| Retail Individual Investor (RII) | 51.05 |
| Total | 37.64 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
Skyline Financial Services Private Limited
Phone: 011-40450193-197
Email: ipo@skylinerta.com
Website: www.skylinerta.com
Lead Managers
- 1Fintellectual Corporate Advisors Pvt.Ltd.
Company Address
Avience Biomedicals Ltd.C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi – 110058
Website: https://avienbio.com/
Phone: 1800-12-04-636
Email: info@avienbio.com
FAQs
- What is the issue size of the Avience Biomedicals SME IPO?The Avience Biomedicals SME IPO has an issue size of ₹30.24 crore. This includes a fresh issue of ₹28.53 crore and an offer for sale (OFS) of NIL.
- What is the price band of the Avience Biomedicals IPO?The price band for the Avience Biomedicals IPO is ₹196 - ₹208 per share.
- What are the bidding dates for the Avience Biomedicals IPO?The Avience Biomedicals IPO will open for bidding on 18 Jun 2026 and close on 22 Jun 2026.
- What is the allotment date for the Avience Biomedicals IPO?The allotment date for the Avience Biomedicals IPO is 23 Jun 2026.
- What is the minimum lot size and investment required for the Avience Biomedicals IPO?The minimum lot size for the Avience Biomedicals IPO is 600 shares and the minimum investment required is ₹1,24,800.
- What is the listing date for the Avience Biomedicals IPO?The listing date for the Avience Biomedicals IPO is .
- What is the Avience Biomedicals IPO grey market premium?The grey market premium (GMP) for the Avience Biomedicals IPO is currently at ₹0, with an expected listing gain of approximately %. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.